Emergent BioSolutions, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

The New York Times published an article on March 31, 2021 reporting on the accidental contamination of coronavirus vaccines developed by Johnson & Johnson and AstraZeneca PLC at an Emergent manufacturing plant in Baltimore. According to reporting by the Associated Press, this Emergent factory where the contamination occurred experienced a series of lapses, as observed in April 2020 by the U.S. Food and Drug Administration in April 2020. On April 1, 2021, Emergent’s stock price fell $12.45 per share, or 13.4%, on this news, to close at $80.46 per share.